Indian Journal of Anaesthesia  
About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions
Home | Login  | Users Online: 2939  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size    




 
 Table of Contents    
LETTER TO EDITOR
Year : 2011  |  Volume : 55  |  Issue : 4  |  Page : 426-427  

Rate of administration of intravenous ondansetron


Department of Anaesthesia and Intensive Care, Vardhman Mahavir Medical College and Safdarjang Hospital, New Delhi, India

Date of Web Publication13-Sep-2011

Correspondence Address:
Smita Prakash
C 17 HUDCO Place, New Delhi - 110 049
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5049.84827

Rights and Permissions

How to cite this article:
Prakash S, Aggarwal M. Rate of administration of intravenous ondansetron. Indian J Anaesth 2011;55:426-7

How to cite this URL:
Prakash S, Aggarwal M. Rate of administration of intravenous ondansetron. Indian J Anaesth [serial online] 2011 [cited 2019 Dec 10];55:426-7. Available from: http://www.ijaweb.org/text.asp?2011/55/4/426/84827

Sir,

Ondansetron, a selective 5- HT 3 receptor antagonist, is a popular drug for prevention and treatment of postoperative nausea and vomiting (PONV) because of its efficacy, safety and lack of drug interactions. Although rare, cardiovascular adverse effects such as sinus bradycardia, atrial fibrillation, prolongation of QTc interval and fatal ventricular tachycardia have been reported following administration of ondansetron. [1],[2],[3],[4] A case of severe bradycardia with respiratory arrest and loss of consciousness has been described. [5] Most of the case reports regarding serious adverse effects, including that reported in Indian Journal of Anaesthesia by Sahu et al., [4] do not describe the rate at which ondansetron had been administered to the patient. It is not uncommon for residents to administer ondansetron as a bolus perioperatively. Not many clinicians are aware that ondansetron 4 to 8 mg iv should be administered over 2 to 5 min [6] and certainly not as a bolus or in less than 30 s. Perhaps slow administration of ondansetron as recommended over 2-5 min would decrease the incidence of potentially life-threatening adverse effects associated with ondansetron.

 
   References Top

1.Moazzam MS, Nasreen F, Bano S, Amir SH. Symptomatic sinus bradycardia: A rare adverse effect of intravenous ondansetron. Saudi J Anaesth 2011;5:96- 7.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of nausea and vomiting: A case report. Can J Anesth 2003;50: 229- 31.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Chandrakala R, Vijayashankara CN, Kumar K, Sarala N. Ondansetron induced ventricular tachycardia. Indian J Pharmacol 2008;40:186- 7.  Back to cited text no. 3
[PUBMED]  Medknow Journal  
4.Sahu S, Karna ST, Agarwal A, Ambesh SP, Srivastava A. Ondansetron causing near fatal catastrophe in a renal transplant recipient. Indian J Anaesth 2011;55:81- 2.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
5.Afonso N, Dang A, Namshikar V, Kamat S, Rataboli PV. Intravenous ondansetron causing severe bradycardia: Two cases. Ann of Card Anaesth 2009;12: 172- 3.  Back to cited text no. 5
    
6.Stoelting RK, Hillier SC, editors. Pharmacology and physiology in anesthetic practice 4 th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2006. p. 444- 55.  Back to cited text no. 6
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1894    
    Printed57    
    Emailed0    
    PDF Downloaded428    
    Comments [Add]    

Recommend this journal